PDF下载 ( 93 KB)
Study on the relationship between hepatitis B virus genotypes and effect of lamivudine therapy.
-
摘要: 探讨乙型肝炎病毒(HBV)基因型与拉米夫定治疗慢性乙型肝炎(CHB)疗效的关系。采用PCR、核酸杂交和酶联显色技术对CHB进行HBV基因分型,观察123例(B型93例和C型30例)CHB患者拉米夫定治疗1年后肝功能、病毒学指标和YMDD变异的变化。ALT复常率为92.47%,HBeAg阴转率为27.96%,HBVDNA阴转率为82.80%,有效应答率为89.25%,与C基因型相比差异有显著性(P<0.05或P<0.005)。B型YMDD变异的发生率为9.68%,显著低于C型的26.67%(P<0.05)。B型对拉米夫定的抗病毒疗效高于C型,YMDD变异的发生率则低于C型。HBV基因型是影响拉米夫定疗效和变异的重要因素之一。Abstract: To study the relationship between hapatitis B virus genotypes and effect of lamivudine therapy on chronic hepatitis B.Plasma samples of 123 patients with chronic hepatitis B were detected and compared by PCR, Microplate, Hybridization-ELISA.All the patients, 93 patients with genotype B and 30 patients with genotype C, received lamivudine therapy for more than one year.Liver function, viral markers and YMDD mutation were detected one year after treatment.The results showed in B genotype, the recovery rate of ALT was 92.47%, the negative conversion rate of HBeAg was 27.96%, the negative conversion rate of HBV DNA was 82.80%, the antiviral response was 89.25% showing a significant difference as compared with genotype C (P<0.05 or P<0.01) .The emergence rate of YMDD mutation in genotype B was significantly lower than that in genotype C (9.68% and 26.67%, P<0.05) .The antiviral response of lamivudine in HBV genotype B is significantly higher than that in genotype C, and the emergence rate of YMDD mutation in genotype B was significantly lower than that in genotype C.HBV genotypes may be an important determinant of lamivudine therapy of chronic hepatitis B.
-
Key words:
- hepatitis B virus /
- Genotype /
- lamivudine /
- therapy /
- YMDD mutation
-
[1]ArauzRuiaP, NorderH, RobertsonBH, etal.GenotypeH∶anew AmerindiangenotypeofhepatitisBvirurevealedinCentalAmerica[J].J Genvirol, 2002, 83 (Pt8) ∶2059-2073. [2]KaoJH, ChenPJ, LaiMY, etal.HepatitisBgenotypescorrelatewithclin icaloutcomesinpatientswithchronichepatitisB[J].Gastroenterology, 2000, 118∶554-559. [3]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19∶56-62. [4]HouJ, SehillingR, JanssenH, etal.MolecularcharacteristicsofhepatitisBvirusgenotypesAconferahigherresponseratetointerferontreatment[J].JHepatol, 2001, 34 (Suppl.1) ∶15. [5]WaiCT, ChuCJ, HussainM, etal.HBVgenotypeBisassociatedwith betterresponsetointerferontherapyinHBeAg (+) chronichepatitisthan genotypeC[J].Hepatology, 2002, 36∶1425-1430. [6]KaoJH, WuNH, ChenPJ, etal.HepatitisBgenotypesandtheresponseto interferontherapy[J].JHepatol, 2000, 33∶998-1002. [7]KaoJH, LiuCJ, ChenDS, etal.hepatitisBviralgenotypesandlamivu dineresistance[J].JHepatol, 2002, 36∶303-304. [8]ZollnerB, PetersenJ, SchroterM, etal.20-foldincreaseinriskof lamivudineresistanceinhepatitisBvirussubtypeadw[J].Lancet, 2001, 357∶934-935. [9]王永忠, 周围平, 李夏亭, 等.乙型肝炎病毒基因分型及临床应用研究[J].中华实验和临床病毒学杂志, 2002, 16∶367-369. [10]AkutaN, SuzukiF, KobayashiM, etal.TheinfluenceofhepatitisBvirus genotypeonthedevelopmentoflamivudineresistancelong-termtreat ment[J].JHepatol.2003, 38∶315-321. [11]曾国兵, 温波娟, 孙剑, 等.乙型肝炎病毒基因型与聚合酶基因异质性[J].中华肝脏病杂志, 2003, 11∶265-267. -
本文二维码
计量
- 文章访问数: 2311
- HTML全文浏览量: 35
- PDF下载量: 707
- 被引次数: 0
下载:
